AKEBIA THERAPEUTICS, INC. (AKBA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 160.87M USD | Liabilities, Current |
| Cash and equivalents | 155.55M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 53.51M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 13.02M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $160.87M | $155.55M | (m) | $53.51M | $13.02M | (m) |
| 2026-03-31 | (m) | $173.88M | $162.64M | (m) | $62.54M | $13.00M | (m) |
| 2025-12-31 | (m) | $162.94M | $184.84M | (m) | $47.03M | $15.61M | (m) |
| 2025-09-30 | (m) | $133.38M | $166.44M | (m) | $66.22M | $18.64M | (m) |
| 2025-06-30 | (m) | $118.72M | $137.31M | (m) | $72.81M | $16.71M | (m) |
| 2025-03-31 | (m) | $91.23M | $113.37M | (m) | $61.54M | $19.73M | (m) |
| 2024-12-31 | (m) | $80.91M | $51.87M | (m) | $34.37M | $16.24M | (m) |
| 2024-09-30 | (m) | $65.71M | $34.02M | (m) | $32.17M | $20.49M | (m) |
| 2024-06-30 | (m) | $107.30M | $39.50M | (m) | $29.77M | $23.87M | (m) |
| 2024-03-31 | (m) | $66.49M | $41.96M | (m) | $26.62M | $25.53M | (m) |
| 2023-12-31 | (m) | $99.87M | $42.92M | (m) | $39.29M | $15.69M | (m) |
| 2023-09-30 | (m) | $79.70M | $46.53M | (m) | $22.59M | $18.44M | (m) |
| 2023-06-30 | (m) | $92.18M | $53.57M | (m) | $19.57M | $20.91M | (m) |
| 2023-03-31 | (m) | $82.94M | $56.95M | (m) | $17.78M | $20.60M | (m) |
| 2022-12-31 | (m) | $124.76M | $90.47M | (m) | $39.18M | $21.76M | (m) |
| 2022-09-30 | (m) | $187.97M | $144.76M | (m) | $23.09M | $40.04M | (m) |
| 2022-06-30 | (m) | $233.68M | $143.89M | (m) | $81.87M | $36.27M | (m) |
| 2022-03-31 | (m) | $253.91M | $174.56M | (m) | $64.58M | $39.42M | (m) |
| 2021-12-31 | (m) | $256.49M | $149.80M | (m) | $50.88M | $38.20M | (m) |
| 2021-09-30 | (m) | $189.21M | $207.20M | (m) | $49.69M | $33.69M | (m) |
| 2021-06-30 | (m) | $165.59M | $246.99M | (m) | $35.01M | $37.90M | (m) |
| 2021-03-31 | (m) | $172.68M | $252.76M | (m) | $35.23M | $44.81M | (m) |
| 2020-12-31 | (m) | $187.15M | $228.70M | (m) | $26.85M | $61.02M | (m) |
| 2020-09-30 | (m) | $181.46M | $169.29M | (m) | $24.47M | $88.24M | (m) |
| 2020-06-30 | (m) | $195.77M | $245.41M | (m) | $39.12M | $104.60M | (m) |
| 2020-03-31 | (m) | $214.15M | $115.37M | (m) | $104.87M | $111.85M | (m) |
| 2019-12-31 | $186.56M | $208.12M | $147.45M | $245.00K | $38.86M | $116.35M | 0.90× |
| 2019-09-30 | $175.27M | $223.15M | $122.89M | $22.73M | $29.65M | $115.99M | 0.79× |
| 2019-06-30 | $165.65M | $185.62M | $87.21M | $49.55M | $28.89M | $122.14M | 0.89× |
| 2019-03-31 | $216.47M | $202.61M | $62.74M | $105.30M | $48.44M | $115.21M | 1.07× |
| 2018-12-31 | $338.06M | $265.69M | $104.64M | $216.75M | $16.67M | $114.25M | 1.27× |
| 2018-09-30 | (m) | $177.40M | $162.43M | (m) | $688.00K | (m) | (m) |
| 2018-06-30 | (m) | $164.42M | $163.53M | (m) | $132.00K | (m) | (m) |
| 2018-03-31 | (m) | $151.42M | $158.17M | (m) | $35.85M | (m) | (m) |
| 2017-12-31 | (m) | $144.35M | $70.16M | (m) | $34.22M | (m) | (m) |
| 2017-09-30 | (m) | $151.36M | $89.60M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $181.59M | $125.39M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $133.46M | $87.25M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $114.27M | $187.34M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $26.14M | $65.83M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $20.93M | $46.18M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $13.41M | $43.44M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $11.87M | $49.78M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $14.17M | $66.71M | (m) | $14.00K | (m) | (m) |
| 2015-06-30 | (m) | $5.90M | $76.25M | (m) | $48.00K | (m) | (m) |
| 2015-03-31 | (m) | $8.84M | $27.89M | (m) | $74.00K | (m) | (m) |
| 2014-12-31 | (m) | $6.88M | $32.78M | (m) | $48.00K | (m) | (m) |
| 2014-09-30 | (m) | $6.52M | $49.67M | (m) | $57.00K | (m) | (m) |
| 2014-06-30 | $105.40M | $4.77M | $95.39M | $9.89M | $113.95K | (m) | 22.10× |
| 2014-03-31 | (m) | $6.12M | $126.32M | (m) | $119.39K | (m) | (m) |
| 2013-12-31 | (m) | $3.90M | $21.22M | (m) | $135.34K | (m) | (m) |
| 2013-09-30 | (m) | (m) | $24.60M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $40.74M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $2.59M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $1.64M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | $5.01M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |